Business
BioLife Solutions to Announce Preliminary 2022 Revenue and Introduce 2023 Revenue Guidance on January 9, 2023
Announcement Precedes Meetings to be Held During the J.P. Morgan Health Care Conference; Updated Investor Presentation Demonstrates Continued Execution to
About this update from Biolife Solutions, Inc.
[{"type":"text","content":"Announcement Precedes Meetings to be Held During the J.P. Morgan Health Care Conference; Updated Investor Presentation Demonstrates Continued Execution to Drive High-Margin, Recurring Revenue\nBOTHELL, Wash., Dec. 19, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies (\"CGT\") and broader biopharma markets, today announced plans to announce preliminary 2022 revenue and introduce 2023 revenue guidance before market open on January 9, 2023, in advance of management's meetings with investors, customers, and partners concurrent with the 41st Annual J.P. Morgan Health Care Conference in San Francisco January 9-12. The Company also announces the availability of an updated investor presentation on its corporate website. \n\n \n \n \n \n \n \n\n \nMichael Rice, Chairman & Chief Executive Officer, commented, \"We are closing 2022 on a strong note with our growth initiatives performing to plan and operational execution continuing to improve our financial performance. Of particular note, we expect to continue to drive a product mix shift to high-margin, recurring revenue over the next few years. BioLife's position as a leading and critical tools and services supplier to the high-growth CGT market was strengthened in 2022, and we are well-positioned for sustained growth as these biologic medicines are established as compelling treatments for large patient populations.\"\nAbout BioLife Solutions\nBioLife Solutions is a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets. Our tools portfolio includes our proprietary CryoStor® and HypoThermosol® biopreservation media for shipping and storage, the ThawSTAR® family of automated, water-free thawing products, evo® cold chain management system, high capacity cryogenic storage freezers, Stirling Ultracold mechanical freezers, SciSafe biologic storage services, and Sexton Biotechnologies cell processing tools. For more information, please visit www.biolifesolutions.com, www.scisafe.com, www.stirlingultracold.com, or www.sextonbio.com and follow BioLife on Twitter.\nCautions Regarding Forward Looking Statements\nThis press release contains \"forward-looking statements\" within the meaning of the Private Securities L...